A team of researchers led by scientists that has developed fluorescent lateral flow test (FLFT) for our early detection cancer rapid tests. A fluorescent lateral flow test (FLFT) is a diagnostic method that combines traditional lateral flow assay technology with fluorescent labels to enhance sensitivity and quantification. Unlike conventional lateral flow tests that use colloidal…
Fluorescent Lateral Flow Testing (FLFT) for Early Cancer Detection Our research team has developed a next‑generation fluorescent lateral flow test (FLFT) to power our ultra‑sensitive rapid cancer detection platform. FLFT technology builds on traditional lateral flow assays but replaces colored particles with fluorescent labels, dramatically increasing sensitivity and enabling true quantitative measurement. Why FLFT Matters…
A distinguished member of a Scientific Advisory Council, which has made significant contributions to cancer immunotherapy, particularly in ovarian cancer. His research focuses on identifying tumor antigens and developing immunotherapeutic strategies, including vaccines and engineered T cells, to enhance the immune system’s ability to combat cancer.
A distinguished member of a Scientific Advisory Council, which has made significant contributions to cancer immunotherapy, particularly in ovarian cancer. His research focuses on identifying tumor antigens and developing immunotherapeutic strategies, including vaccines and engineered T cells, to enhance the immune system’s ability to combat cancer.
AbulKalam M. Shamsuddin, M.B.,B.S., Ph.D., served as Professor of Pathology at the University of Maryland School of Medicine in Baltimore, MD, for over 43 years, Senior Scientist at National Cancer Institute (NCI), distinguished by numerous awarded U.S. patents. He earned his medical degree from Dhaka Medical College at the University of Dhaka and subsequently completed…
Carbohydrate antigen 72-4 (CA72-4) is a tumor-associated glycoprotein frequently studied as a biomarker for cancer, particularly gastric and gynecological malignancies. Here’s a detailed overview based on current research: Overview and Diagnostic Role Prognostic and Monitoring Value Detection Technologies Age and Gender Effects Therapeutic Potential Conclusion CA72-4 is a valuable biomarker for monitoring and prognosis in…
AI-Driven Biomarkers: Transforming Cancer Detection Through Multimodal Intelligence Introduction The integration of artificial intelligence (AI) into healthcare has revolutionized biomedical research, diagnostics, and patient care. One of the most promising applications lies in the development of AI-driven biomarkers—computationally identified features from diverse biological data types that can be used to detect, diagnose, or predict disease….
RNA Polymerase II Levels in Histone Genes: A Predictive Biomarker for Tumor Aggressiveness and Recurrence Introduction Histone genes play a fundamental role in DNA packaging and chromatin structure, and their expression is tightly regulated during the cell cycle, particularly in S-phase. RNA Polymerase II (RNAPII), the enzyme responsible for transcribing protein-coding genes, including replication-dependent histone…
FOR IMMEDIATE RELEASE Contact: Jonathan Adam Barash Email: [email protected] Phone: 516‑900‑2606 Website: www.oncofirmdiagnostics.com OncoFirm Diagnostics Corp. Announces Launch and Opens First Funding Round Up to $10 Million Advancing Early Cancer Detection Through Rapid, Antigen‑Based Screening Technology Port Washington, New York — April 7 — OncoFirm Diagnostics Corp., an emerging leader in medical diagnostics, today announced…
FOR IMMEDIATE RELEASEContact: Jonathan Adam BarashEmail: [email protected]: 516-900-2606Website: www.oncofirmdiagnostics.com OncoFirm Diagnostics Corp. Announces Launch and Opens First Round Funding Opportunities Up to $10 Million Revolutionizing Early Cancer Detection Through Rapid, Antigen-Based Screening Technology Port Washington, New York — April 7 — OncoFirm Diagnostics Corp., a cutting-edge medical diagnostics company, today announced its official launch and…
